Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 33Paclitaxel 27Cyclophosphamide 25Carboplatin 23olaparib 21Fulvestrant 15fludarabine 14Trastuzumab 14aldesleukin 13Docetaxel 13Early Intervention, Educational 12Surveys and Questionnaires 11veliparib 10palbociclib 10Methods 10Gemcitabine 10Blood Specimen Collection 10Nivolumab 9Flow Cytometry 9Biopsy 9Bevacizumab 9sargramostim 8niraparib 7liposomal doxorubicin 7Therapeutics 7Taxes 7Standard of Care 7Psychiatric Rehabilitation 7Magnetic Resonance Spectroscopy 7talazoparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × vatalanib × Gynecologic × Clear all
NCT00268918 2018-07-27

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

Dana-Farber Cancer Institute

Phase 1 Completed
24 enrolled
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡